Annual report pursuant to Section 13 and 15(d)

Original AL001 License: (Details)

v3.22.2
Original AL001 License: (Details)
12 Months Ended
Apr. 30, 2022
USD ($)
A L001 License [Member] | Pre I N D Meeting [Member]  
Product Liability Contingency [Line Items]  
Payment $ 50,000
Due Date  Completed September 2019
A L001 License [Member] | Ind Application Filing [Member]  
Product Liability Contingency [Line Items]  
Payment $ 65,000
Due Date  Completed June 2021
A L001 License [Member] | Upon First Dosing of Patient in Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 190,000
Due Date  Completed December 2021
A L001 License [Member] | Upon Completion of First Patient Dosing [Member]  
Product Liability Contingency [Line Items]  
Payment $ 500,000
Due Date  Completed March 2022
A L001 License [Member] | Upon Completion of First Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 1,250,000
Due Date  12 months from completion of the first Phase II clinical trial
A L001 License [Member] | Upon Fda Approval [Member]  
Product Liability Contingency [Line Items]  
Payment $ 10,000,000
Due Date  8 years from the effective date of the agreement
A L002 License [Member] | Pre I N D Meeting [Member]  
Product Liability Contingency [Line Items]  
Payment $ 50,000
Due Date Completed January 2022
A L002 License [Member] | Ind Application Filing [Member]  
Product Liability Contingency [Line Items]  
Payment $ 50,000
Due Date 12 months from IND application filing date
A L002 License [Member] | Upon First Dosing of Patient in Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 175,000
Due Date 12 months from first patient dosed in Phase I
A L002 License [Member] | Upon Completion of First Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 500,000
Due Date 24 months from completion of first Phase I clinical trial
A L002 License [Member] | Upon Fda Approval [Member]  
Product Liability Contingency [Line Items]  
Payment $ 10,000,000
Due Date 7 years from the effective date of the agreement
A L002 License [Member] | Upon First Patient Treated in Phase3 Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 1,000,000
Due Date 12 months from completion of the first Phase II clinical trial
Additional A L001 License [Member] | Ind Application Filing [Member]  
Product Liability Contingency [Line Items]  
Payment $ 50,000
Due Date Upon IND application filing
Additional A L001 License [Member] | Upon First Dosing of Patient in Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 150,000
Due Date 12 months from IND filing date
Additional A L001 License [Member] | Upon Completion of First Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 400,000
Due Date 12 months from first patient dosing
Additional A L001 License [Member] | Upon Fda Approval [Member]  
Product Liability Contingency [Line Items]  
Payment $ 8,000,000
Due Date 8 years from the effective date of the agreement
Additional A L001 License [Member] | Upon First Patient Treated in Phase3 Clinical Trial [Member]  
Product Liability Contingency [Line Items]  
Payment $ 1,000,000
Due Date 36 months from completion of the first Phase II clinical trial